Answers are grounded in this paper and cite their sources.
Substantial efforts in adoptive T-cell therapy have centered on boosting T-cell activity against tumors. However, a crucial yet overlooked factor is that the onset and maintenance of T-cell responses are highly dependent on innate immunity. Here, we developed a strategy of engineering tumors with bacterial antigens via click chemistry to cross-regulate innate-adaptive immunity, thereby enhancing the efficacy of adoptive T-cell therapy in solid tumors. The targeted delivery of bacterial antigens is mediated by azido sugar liposomes (TALP) for introducing azide groups on tumors and dibenzocyclooctyne-decorated bacterial membranes (DBCO-BM) to endow tumor cells with the innate immunogenicity of bacteria. Our study reveals that tumors with exposed bacterial antigens trigger innate immune responses for direct tumor killing and drive T-cell tumor infiltration to launch adaptive immunity. The antitumor functions of adoptive T cells are significantly augmented with the cross-activation of innate-adaptive immunity. This study highlights the potential of innate immunity in addressing the suboptimal response of adoptive T cells in solid tumors.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: